(Q45196993)

10 December 2017

Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study (English)

1 reference

10 December 2017

0 references

1 reference

4

Anders Oden

1 reference

10 December 2017

3

John A Kanis

1 reference

10 December 2017

2

Olof Johnell

1 reference

10 December 2017

Fredrik Borgström

1

1 reference

10 December 2017

David Sykes

series ordinal

5

1 reference

10 December 2017

Bengt Jönsson

series ordinal

6

1 reference

10 December 2017

1 January 2004

1 reference

10 December 2017

13

1 reference

inferred from page(s)

published in

PharmacoEconomics

1 reference

10 December 2017

22

1 reference

10 December 2017

17

1 reference

10 December 2017

1153-1165

1 reference

https://scigraph.springernature.com/pub.10.2165/00019053-200422170-00005

10 December 2017

0 references

cites work

The risk and burden of vertebral fractures in Sweden

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422170-00005

Hip fractures in the elderly: a world-wide projection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422170-00005

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422170-00005

Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422170-00005

A computer simulation model for cost-effectiveness analysis of cardiovascular disease prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422170-00005

Cost-effectiveness of preventing hip fracture in the general female population.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422170-00005

Risk of hip fracture derived from relative risks: an analysis applied to the population of Sweden.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422170-00005

Models for assessing the cost-effectiveness of the treatment and prevention of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422170-00005

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422170-00005

Hormone replacement therapy and risk of hip fracture: population based case-control study. The Swedish Hip Fracture Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422170-00005

21 January 2018

Bone-density measurement

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422170-00005

The effect of postmenopausal estrogen therapy on bone density in elderly women

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422170-00005

Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422170-00005

The association of radiographically detected vertebral fractures with back pain and function: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422170-00005

Incidence of vertebral fracture in europe: results from the European Prospective Osteoporosis Study (EPOS).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422170-00005

Long-term risk of osteoporotic fracture in Malmö.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422170-00005

Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422170-00005

Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422170-00005

Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. Study of Osteoporotic Fractures Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422170-00005

Costs of coronary heart disease and stroke: the case of Sweden.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422170-00005

The cost-effectiveness of routine postoperative radiotherapy after sector resection and axillary dissection for breast cancer stage I. Results from a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422170-00005

Accounting for future costs in medical cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422170-00005

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422170-00005

Impact of hip and vertebral fractures on quality-adjusted life years.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422170-00005

The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from the Multiple Outcomes of Raloxifene Evaluation Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422170-00005

A case-control study of quality of life and functional impairment in women with long-standing vertebral osteoporotic fracture.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422170-00005

The cost utility of bisphosphonate treatment in established osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422170-00005

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422170-00005

A systematic review of health state utility values for osteoporosis-related conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422170-00005

Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422170-00005

Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Fracture Intervention Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422170-00005

Association between vertebral fracture and increased mortality in osteoporotic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422170-00005

Mortality after all major types of osteoporotic fracture in men and women: an observational study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422170-00005

NICE: faster access to modern treatments? Analysis of guidance on health technologies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422170-00005

Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422170-00005

Inpatient hospital and post-acute care for vertebral fractures in women

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422170-00005

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422170-00005

Bone Mass and the Risk of Breast Cancer among Postmenopausal Women

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422170-00005

The Cost Effectiveness of Hypertension Treatment in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422170-00005

Risk of Mortality Following Clinical Fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422170-00005

Increments in Bone Mineral Density of the Lumbar Spine and Hip and Suppression of Bone Turnover Are Maintained after Discontinuation of Alendronate in Postmenopausal Women

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200422170-00005

Excess mortality after hospitalisation for vertebral fracture

21 January 2018

1 reference

12 December 2020

Cost-effectiveness of bisoprolol in chronic heart failure

1 reference

12 December 2020

Treatment of established osteoporosis: a systematic review and cost-utility analysis.

1 reference

12 December 2020

US and UK health economics: two disciplines separated by a common language?

1 reference

12 December 2020

Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial

1 reference

12 December 2020

Cost-effectiveness of fracture prevention in established osteoporosis.

1 reference

12 December 2020

A computer model to analyze the cost-effectiveness of hormone replacement therapy

1 reference

12 December 2020

Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group

1 reference

12 December 2020

Economic assessment based on a clinical study of risedronate. Fracture prevention in elderly women with osteoporosis is cost-effective

1 reference

12 December 2020

Intervention thresholds for osteoporosis

1 reference

12 December 2020

Ten-year risk of osteoporotic fracture and the effect of risk factors on screening strategies

1 reference

12 December 2020

Incremental cost of medical care after hip fracture and first vertebral fracture: the Rotterdam study

1 reference

12 December 2020

10.2165/00019053-200422170-00005

Identifiers

DOI

1 reference

Dimensions Publication ID

10 December 2017

0 references

1 reference